Recruiting

Pain Ease

Sponsor:

Queen's Medical Center

Code:

NCT06933381

Conditions

Reducing Pain With Nexplanon Implant Insertion

Eligibility Criteria

Sex: Female

Age: 14+

Healthy Volunteers: Accepted

Interventions

Vapocoolant spray

Placebo

Study Details

Brief summary:

The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

Conditions

Reducing Pain With Nexplanon Implant Insertion

Study ID

NCT06933381

Start date

Jun 16, 2025

Status verified date

Jan, 2026

Completion date

May 1, 2026

Anticipated

Primary completion date

Apr 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 14+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • At least 14 years or older
  • Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
  • English speaking
  • Able and willing to sign the informed consent form and agree to terms of the study

Exclusion Criteria:

  • Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
  • Known previous exposure to vapocoolant spray
  • Nexplanon removal and reinsertion same day during visit in the same arm
  • Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
  • Unable to provide written, informed consent in English

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Vapocoolant Spray

This is the study arm. Participants in this arm of the study will receive Pain Ease vapocoolant spray during their Nexplanon implant insertion in the arm. They will receive the spray on their arm right before lidocaine injection is administered for Nexplanon insertion procedure. Pain Ease vapocoolant spray is FDA approved for use on skin prior to common needle-stick procedures like intravenous (IV) starts and vaccines. The investigators will use the spray in a similar fashion, to help with the pain of lidocaine injection during Nexplanon insertion procedures. Physicians will do the Nexplanon procedure before any other procedures if patient has multiple procedures scheduled the same day.

placebo comparator: Nature's Tears

This is the placebo. This group will receive Nature's Tears, which is a saline spray that does not offer analgesic effects.

Interventions

Vapocoolant spray

Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.

Placebo

Nature's Tears will be applied to the arm as a placebo spray

Primary outcome measure

  • Pain with lidocaine injection [ Time Frame: Immediately after lidocaine injection ]

Central Contacts and Locations

Central contacts

Sarah Murayama, MD

808-783-0298smura@hawaii.edu

Mary Tschann, PhD

808-375-3785mtschann@hawaii.edu

Locations

Queens Medical Center POB 2 Suite 402

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Sarah Murayama, MD

808-783-0298smura@hawaii.edu

Mary Tschann, PhD

808-375-3785

Principal Investigator:

Sarah Murayama, MD

Queens Medical Center POB1 Clinic 1004

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Sarah Murayama, MD

808-783-0298smura@hawaii.edu

Mary Tschann, PhD

808-375-3785mtschann@hawaii.edu

Principal Investigator:

Sarah Murayama, MD

More Information

Sponsor

Queen's Medical Center

Last update posted

Jan 9, 2026

Last verified

Jan, 2026

Keywords

  • Vapocoolant spray
  • Pain with Nexplanon insertion
  • Contraceptive implant insertion
  • Vapocoolant

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Queen's Medical Center on 2026-01-09.